Genomic-based solutions can help identify which cancer patients will respond better to treatment based on biomarkers, said David Fabrizio of Foundation Medicine, Inc.
Genomic-based solutions can help identify which cancer patients will respond better to treatment based on biomarkers, said David Fabrizio of Foundation Medicine, Inc.
Transcript (slightly modified)
Do you think the immunotherapy field needs a different approach to predict patient response to treatment?
Yeah, absolutely. I think right now IHC [immunohistochemistry] is the current method, and I spoke to some of the limitations, I think there are significant limitations to IHC. I think we need genomic-based solutions, quantitative solutions that can be universally adopted. So something like tumor mutational burden [TMB], which can be measured through comprehensive genomic profiling, is a solution.
And we know this because we’ve looked at the utility over more than 500 patients right now, in disease areas that include non-small cell lung cancer, bladder cancer, and metastatic melanoma, and we’ve published these results showing that you can identify biomarker-positive patients that in some cases lived 3 times longer than the negative group without their disease getting any worse, and that’s in lung cancer. In the bladder and melanoma studies, the biomarker-positive groups for TMB weren’t reached, the median survival wasn’t reached, compared to the ones who were negative. So it does have resounding clinical utility, and I think we’re going to start to see that expand to other indications.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More
Dr Al Benson on Reimbursement for Supportive Care When Treating Patients With Cancer
March 22nd 2024Al Benson, MD, FACP, FACCC, FASCO, medical oncologist at Northwestern University Feinberg School of Medicine and associate director of the Robert E. Tillery Comprehensive Cancer Center, discussed findings from a national survey assessing barriers to comprehensive cancer care delivery.
Read More